Expanded Access Policy
EXPANDED ACCESS POLICY
Aurinia Pharmaceuticals Inc. (Aurinia) is committed to developing safe and effective therapies for serious diseases that impact patients and their families. To do that, Aurinia enrolls and conducts the clinical trials necessary to support regulatory approval to make our therapies broadly available to patients as quickly as possible. The Company believes that clinical trials provide the best way to generate the safety and efficacy data needed to obtain marketing approval of Aurinia’s investigational drugs and to achieve its mission of advancing therapies to address areas of high unmet medical need.
Expanded access, sometimes referred to as compassionate use, refers to the use of an investigational drug outside of a clinical trial when the primary purpose is to diagnose, prevent, treat, or monitor a patient with a serious or life-threatening condition, who has exhausted all available medical options and is unable to enroll in available clinical trials. At this time, Aurinia is unable to make its investigational drugs available to patients outside of a clinical trial.
If you have additional questions about clinical trials, or alternative therapies that may be available to you through other companies and that may be appropriate for you, please speak with your physician.
Please note that Aurinia may revise this policy at any time. The website and policy will be updated to reflect any such revisions as they are implemented.